SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ABTI Alpha-Beta Technology
ABTI 0.0002000.0%Nov 7 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Rosemary who wrote ()5/30/1997 4:34:00 PM
From: Jonathan Rothschild   of 572
 
Nice move today on 160 M volume. I think we're getting close. One of the big fears is the string of failures in sepsis-related indications (e.g. Xoma, Synergen, Centacor). I wonder if post-surgical infection is similar to sepsis. Is there any way to assess the efficacy of Betafectin in phase 2 studies as predictive of a positive outcome based on the severe condition of these hospitalized patients. Is this drug oral or injectable? Does it work on a specific region (e.g. g.i. tract) or is systemic?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News